Page 23 - GPD-3-1

Gene & Protein in Disease Enhancing fertility with CRISPR

CRISPR-Cas9 in gynecological cancer research. Clin Genet. Idea? ; 2021. p. 111-120.
2020;97(6):827-834.
105. Ayanoğlu FB, Elçin AE, Elçin YM. Bioethical issues in
doi: 10.1111/cge.13717 genome editing by CRISPR-Cas9 technology. Turk J Biol.
2020;44(2):110-120.
94. Cai J, Wu D, Jin Y, Bao S. Effect of CMB carrying PTX and
CRISPR/Cas9 on endometrial cancer naked mouse model. doi: 10.3906/biy-1912-52
J Healthc Eng. 2022;2022:7119195.
106. Garland-Thomson R. How we got to CRISPR: The dilemma
doi: 10.1155/2022/7119195 of being human. Perspect Biol Med. 2020;63(1):28-43.
95. Wu R, Stolfi C, Zhai Y, Fearon ER, Cho KR. Abstract doi: 10.1353/pbm.2020.0002
AP16: MODELING endometrioid and high grade serous 107. Actis AM. Cuestiones éticas de la edición genética mediante
carcinomas in the mouse using crispr/cas9-mediated la tecnología CRISPR-Cas9. Revista de Bioética y Derecho.
somatic gene editing in fallopian tube epithelium. Clin 2021;53:203-214.
Cancer Res. 2019;25:AP16.
108. Doxzen K, Halpern J. Focusing on human rights:
doi: 10.1158/1557-3265.OVCASYMP18-AP16
A framework for CRISPR germline genome editing ethics
96. Chen XZ, Guo R, Zhao C, et al. A novel anti-cancer and regulation. Perspect Biol Med. 2020;63(1):44-53.
therapy: CRISPR/Cas9 gene editing. Front Pharmacol. doi: 10.1353/pbm.2020.0003
2022;13:939090.
109. DiEuliis D, Giordano J. Gene editing using CRISPR/Cas9:
doi: 10.3389/fphar.2022.939090
Implications for dual-use and biosecurity. Protein Cell.
97. Kang XJ, Caparas CIN, Soh BS, Fan Y. Addressing challenges 2018;9(3):239-240.
in the clinical applications associated with CRISPR/Cas9
technology and ethical questions to prevent its misuse. doi: 10.1007/s13238-017-0493-4
Protein Cell. 2017;8(11):791-795. 110. Barrangou R, Doudna JA. Applications of CRISPR
technologies in research and beyond. Nat Biotechnol.
doi: 10.1007/s13238-017-0477-4
2016;34(9):933-941.
98. Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges doi: 10.1038/nbt.3659
of CRISPR-Cas gene-editing to disease treatment in clinics.
Precis Clin Med. 2021;4(3):179-191. 111. Hammond AM, Kyrou K, Gribble M, et al. Gene-drive
suppression of mosquito populations in large cages as a
doi: 10.1093/pcmedi/pbab014
bridge between lab and field. Nat Commun. 2021;12: 4589.
99. Rasul MF, Hussen BM, Salihi A, et al. Strategies to overcome
the main challenges of the use of CRISPR/Cas9 as a doi: 10.1038/s41467-021-24790-6.
replacement for cancer therapy. Mol Cancer. 2022;21(1):64. 112. Godwin J, Serr M, Barnhill-Dilling SK, et al. Rodent gene
drives for conservation: Opportunities and data needs. Proc
doi: 10.1186/s12943-021-01487-4
R Soc B. 2019;286(1914):20191606.
100. Li W, Huang C, Chen J. The application of CRISPR/Cas
mediated gene editing in synthetic biology: Challenges and doi: 10.1098/rspb.2019.1606
optimizations. Front Bioeng Biotechnol. 2022;10:890155. 113. Brown EA, Eikenbary SR, Landis WG. Bayesian network-
based risk assessment of synthetic biology: Simulating
doi: 10.3389/fbioe.2022.890155
CRISPR-Cas9 gene drive dynamics in invasive rodent
101. Yang Y, Xu J, Ge S, Lai L. CRISPR/Cas: Advances, limitations, management. Risk Anal. 2022;42(12):2835-2846.
and applications for precision cancer research. Front Med. doi: 10.1111/risa.13948
2021;8:649896.
114. Orr TJ, Hayssen V. The female snark is still a boojum:
doi: 10.3389/fmed.2021.649896
Looking toward the future of studying female reproductive
102. Dohn MN. Preventing an Era of” New Eugenics”: An biology. Integr Comp Biol. 2020;60(3):782-795.
argument for federal funding and regulation of gene editing
research in human embryos. Richmond J Law Technol. doi: 10.1093/icb/icaa091
2018;25:1. 115. Otabe T, Nihongaki Y, Sato M. Optical control of genome
editing by photoactivatable Cas9. In: Mammalian Cell
103. Hashmi F. Necessity or vanity: Designer babies, CRISPR,
and the future of genetic modifications. Int J Sci Res Manag. Engineering: Methods and Protocols. Berlin: Springer; 2021.
p. 225-233.
2019;7(11);B-2018-35-41.
doi: 10.1007/978-1-0716-1441-9_13
104. Ranisch R. When CRISPR Meets Fantasy: Transhumanism and
the Military in the Age of Gene Editing. In: Transhumanism: 116. Farris MH, Texter PA, Mora AA, et al. Detection of
The Proper Guide to a Posthuman Condition or a Dangerous CRISPR-mediated genome modifications through altered

Volume 3 Issue 1 (2024) 15 https://doi.org/10.36922/gpd.2701